Edition:
India

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

2.49USD
19 Jan 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.49
Open
$2.47
Day's High
$2.61
Day's Low
$2.46
Volume
502,826
Avg. Vol
1,268,575
52-wk High
$6.96
52-wk Low
$0.67

Chart for

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)

Overall

Beta: 3.00
Market Cap(Mil.): $526.55
Shares Outstanding(Mil.): 104.68
Dividend: --
Yield (%): --

Financials

BRIEF-Mannkind, On Jan 18, Co, Unit Entered Into Exchange, Sixth Amendment To Facility Agreement With Deerfield

* MANNKIND - ‍ ON JAN 18, CO AND UNIT ENTERED INTO AN EXCHANGE AND SIXTH AMENDMENT TO FACILITY AGREEMENT WITH DEERFIELD - SEC FILING​

19 Jan 2018

BRIEF-Mannkind Q3 loss per share $0.31

* Mannkind Corporation reports 2017 third quarter financial results

08 Nov 2017

BRIEF-Mannkind restructures near-term debt obligations

* Mannkind Corp - ‍extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock​

23 Oct 2017

BRIEF-Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

* Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

23 Oct 2017

BRIEF-Mannkind Corp resolved to voluntary delist from Tel Aviv Stock Exchange Ltd

* Mannkind corp - ‍on august 4, board resolved to voluntary delist its common stock from tel aviv stock exchange ltd - sec filing​

08 Aug 2017

BRIEF-MannKind Corporation reports 2017 second quarter financial results

* Q2 revenue $2.2 million Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-MannKind and One Drop partner to launch the A-one clinical trial

* MannKind and One Drop partner to launch the A-one clinical trial

07 Aug 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.349.50 +7.50
Pfizer Inc. (PFE.N) $36.94 -0.05
Sanofi SA (SASY.PA) €72.95 +0.58
Eli Lilly and Co (LLY.N) $85.49 -0.33
Nektar Therapeutics (NKTR.OQ) $71.59 +1.43
Albireo Pharma Inc (ALBO.OQ) $33.00 +3.53

Earnings vs. Estimates